Subtype
Pancreatic Carcinoma
CI-CAN-00003562Explore in graph →
488 active trials5 approved drugs31 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003562Explore in graph →
Clinical trials
1,381 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. | terminated | Early Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT05841706 | Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer | terminated | Early Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 10, 2025 |
| NCT03890198 | A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma | terminated | Early Phase 1 | 2 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT03481920 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer | terminated | Early Phase 1 | 7 | PH Research, S.L.OTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT01962909 | Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer | terminated | Early Phase 1 | 3 | University of VirginiaOTHER | 1 | Mar 18, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Oct 10, 2025source: clinicaltrials